We simultaneously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiotropy and the relationship between these clinically related diseases. Using high-density genotype data from more than 86,000 individuals of European ancestry, we identified 244 independent multidisease signals, including 27 new genome-wide significant susceptibility loci and 3 unreported shared risk loci. Complex pleiotropy was supported when contrasting multidisease signals with expression data sets from human, rat and mouse together with epigenetic and expressed enhancer profiles. The comorbidities among the five immune diseases were best explained by biological pleiotropy rather than heterogeneity (a subgroup of cases genetically identical to those with another disease, possibly owing to diagnostic misclassification, molecular subtypes or excessive comorbidity). In particular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is likely the result of a unique disease, which is genetically distinct from classical inflammatory bowel disease phenotypes.
Genome-wide association studies (GWAS) have shown overlap in the genetic susceptibility to human diseases that affect a range of tissues. This overlap is most notable in immune-mediated diseases 1,2 , including the clinically related conditions ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis (PSC) and ulcerative colitis. Comorbidity of these conditions in the same individuals and increased risk of any of these conditions in the family members of cases have been extensively documented 3, 4 . Recently, a large-scale discovery-driven analysis of temporal disease progression patterns using data from an electronic health registry covering the whole population of Denmark found substantial populationwide comorbidity 5 . This raises the possibility of a hidden molecular taxonomy that differs from the traditional classification of disease by organ or system. Cross-disease genetic studies provide an opportunity to resolve overlapping associations into discrete pathways and explore details of apparently shared etiologies.
In this study, we combined Immunochip genotype data for 52,262 cases and 34,213 controls of European ancestry, currently the largest available genetic data sets in five clinically related seronegative immune-driven phenotypes (ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis), to explore the extent of sharing of genetic susceptibility loci. The aims of this cross-phenotype study were (i) to identify subsets of the five phenotypes with shared genetic risk loci using a cross-phenotype meta-analysis approach; (ii) to identify additional susceptibility loci; (iii) to investigate comorbidity and pleiotropy among these phenotypes; and (iv) to improve the understanding of shared pathways and biological mechanisms common to subsets of the phenotypes studied.
RESULTS

Cross-phenotype association analysis
We analyzed Immunochip genotype data for 52,262 cases of ankylosing spondylitis (8, 726 ), Crohn's disease (19, 085) , psoriasis (6, 530) , Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci PSC (3, 408) and ulcerative colitis (14, 413 ) and 34,213 healthy controls ( Supplementary Table 1 ) using variants with a minor allele frequency (MAF) >0.1% to examine the shared and distinct genetic etiology for these diseases (Online Methods). By using Immunochiponly data, we were able to perform uniform and central quality control of all batches, thus reducing potentially existing batch effects (Online Methods). Next, we used a recently published subset-based meta-analysis approach (SBM) 6 to exhaustively explore all subsets of disease combinations for the presence of association signals. This method identifies the best subset of non-null studies while in parallel accounting for multiple-hypothesis testing and a fixed control group (Online Methods). By performing primary SBM analyses, we identified 166 genome-wide significant (P SBM < 5 × 10 −8 ) loci outside the major histocompatibility complex (MHC) region (chromosome 6 region at 25-34 Mb) ( Supplementary Fig. 1 ). Three of these 166 loci (rs2042011 at MIR1208, rs2812378 at CCL21-FAM205A and rs1893592 at UBASH3A) have not been reported previously for any of the five diseases under study and thus are new shared risk loci. SNP associations at UBASH3A (21q22.3) and CCL21 (9p13.3) have been reported previously for other autoimmune disorders 7, 8 . These three new loci would have been missed using single-disease analyses alone. To avoid any loss of power, where variants were only associated with a single phenotype, we carried out single disease versus control subsearches on any SNPs that achieved P SBM < 5 × 10 −7 in the primary analysis. Using this SBM-directed approach, we identified 27 new genome-wide significant disease associations (P disease < 5 × 10 −8 ), including 17 new genome-wide significant loci for ankylosing spondylitis, 6 loci for Crohn's disease and 4 loci for PSC ( Fig. 1,  Supplementary Fig. 2 and Supplementary Table 2 ). Twenty-four of these 27 associations were also genome-wide significant in the primary SBM analyses (P SBM < 5 × 10 −8 ), thus leading to a total of 169 non-MHC risk loci. To identify additional independent association signals within the 169 non-MHC risk loci, we performed a stepwise conditional SBM analysis following a recently published stepwise conditional SBM fine-mapping approach 9 (Online Methods). In total, we identified 244 independent association signals, with 187 signals shared by at least two of the five diseases under study (Supplementary Figs. 3-5 and Supplementary Table 3 ). We estimated the heritability explained by these 244 variants for each disease (Fig. 2) and for all pairwise disease comparisons ( Supplementary  Fig. 6 ). The ten pairwise comparisons of disease-associated alleles showed diverse patterns of sharing with respect to the size and direction of allelic effects and the number of unique associations (Supplementary Fig. 6 ).
Functional annotation of associated variants
We functionally annotated the 244 risk alleles from the 169 distinct loci (Online Methods). For 210 association signals (86.1%), the lead variant was within 10 kb of a known gene, and 34 signals were classified as occurring in intergenic regions (>10 kb distant to a gene) (Supplementary Table 4 ). The analysis identified 16 coding variants (14 missense, 1 frameshift and 1 splice donor) in genes that were previously implicated in immune-mediated diseases (Supplementary Table 5 ). Eight of these variants (located in PTPN22, GPR35, MST1, CD6, NOD2 (two variants), TYK2 and CARD9) have been associated before with one of the traits included in this study, and six (GCKR, IFIH1 (two variants), SH2B3, SMAD3 and TYK2) have been associated with another phenotype, either listed in the GWAS catalog 10 or in ImmunoBase. Two of the genes carrying a coding variant (TLR4 and PRKCQ) have previously been suggested as candidate loci, but robust association signals were still lacking ( Supplementary Table 5 ).
We further checked for variants in high linkage disequilibrium (LD; r 2 >0.8) with the identified variants using 1000 Genomes Project haplotypes and found that, in total, 46 of the identified signals were highly correlated with 57 coding variants (48 missense, 2 stop-gain, 3 spliceregion, 1 frameshift and 3 regulatory variants; Supplementary Table 5 ). We found that 40 of the 57 coding variants, from 30 loci, had been described in previous GWAS or Immunochip studies involving one of the traits included in this study or another phenotype. Additionally, a further nine variants have been mentioned as candidate variants in autoimmune disease publications. Eight coding variants (seven missense and one stop gain; all in high LD with our lead variants), located in EFNA1, FCGR2A, HSPA6, C7orf72 and FAM118A, have not been described before in relation to any immune-mediated phenotype.
eQTL analysis in peripheral blood
Analyses of cis expression quantitative trait locus (eQTL) microarray data from whole peripheral blood samples of an independent control cohort comprising 2,360 unrelated individuals 11, 12 (Online Methods) identified cis effects for 132 (false discovery rate (FDR)-adjusted P FDR < 0.05; Supplementary Table 6 ) of the 244 disease-associated SNPs from Supplementary Table 3a . Five of these represent the best eQTL SNP, and another five represent the best secondary eQTL SNP independent from the best eQTL SNP at a given locus.
Pathway, cell type and annotation enrichment analyses
We tested for enrichment between SNPs in associated loci and various types of genomic annotations using GoShifter 13 . We used 620 different annotations from the US National Institutes of Health (NIH) Roadmap Epigenomics 14 and FANTOM5 (ref. 15 ) projects to look for enrichment of histone modifications and expressed enhancers, respectively ( Supplementary Tables 7 and 8 ). The results from the SBM association analysis were separated into groups including all 244 identified variants, variants shared by three or more phenotypes and variants associated with a single phenotype ( Supplementary Table 9 ). In the Roadmap Epigenomics enrichment analysis, using a significance threshold of P < 1 × 10 −3 , the inflammatory bowel disease (IBD) and psoriasis phenotype subsets showed enrichment for acetylation of histone H3 at lysine 27 (H3K27ac) in CD3 primary cells and for H3K27ac in adipose tissue, respectively (Supplementary Table 10 ). The 'all variants' (n = 244) analysis showed enrichment for trimethylation of histone H3 at lysine 4 (H3K4me3; for which the largest number of cell types were analyzed by the Roadmap Epigenomics consortium and which highlights transcribed promoters and transcription start sites (TSSs) 16 ) in the HUES64 cell line (representing undifferentiated cells), CD34 + cells (bone marrow cells) and natural killer cells (CD56). The FANTOM5 data analysis showed enrichment for enhancers expressed in T cells (Crohn's disease and the 'all variants' group) and also natural killer cells for Crohn's disease. However, only the enrichment for enhancers expressed in T cells in the 'all variants' group met the significance threshold of P = 0.05/620 = 8.06 × 10 −5 required with Bonferroni correction.
To test which candidate genes from the associated loci ( Supplementary Table 3a ) are highly expressed in which tissues and to define disease relationships at the expression level, we conducted pathway and tissue/cell type enrichment analyses using DEPICT 17 , with 77,840 microarray expression profiles from human, rat and mouse and 209 tissue/cell type annotations 18 (Online Methods). Even when correcting for the biased Immunochip gene content, our DEPICT results confirmed that the genes from the 169 non-MHC genome-wide significant susceptibility loci reported herein show greatest relevance for the regulation of immune response pathways ( Supplementary  Fig. 7 ) and the hematopoietic system ( Supplementary Fig. 8 ).
A r t i c l e s
We further generated a protein-protein interaction (PPI) network (111 gene nodes and 65 edges; Supplementary Fig. 9 ) based on five prioritized gene sets for the ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis SNP sets ( Supplementary  Table 9 ), from DEPICT analyses and reference PPI data from ConsensusPathDB 19 (Online Methods). We observed that 36 gene nodes from this PPI network were connected in one single large component ( Supplementary Fig. 9 ). We then evaluated the potential role of these genes for their 'druggability' by linking genes within this core network to drugs using DrugBank (Online Methods). Because the nature and effect of the interaction between a drug and an encoded protein is mostly unknown (for example, some drugs we identified have effects opposite to what we aim for), we performed a manual literature search to assess which of the identified drugs show evidence or could potentially be promising for any of the diseases under study by using PubMed (last search 1 July 2015) and ClinicalTrials.gov. All drugs were selected on the basis of evidence from phase I, II and/or III randomized clinical trials (RCTs) or published animal studies. Nine drug target genes overlapped with the 36 genes from the core network ( Fig. 3) . Although further investigations are necessary, we propose that target gene-drug combinations selected by this approach could represent promising candidates for novel drug discovery in the treatment of ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis. For example, novel CCR2 antagonists such as MLN-1202 and the CCR5 antagonists INCB9471 and AMD-070 are potential new drugs for treatment of ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis.
Bayesian multinomial regression for model selection
To compare different disease models for each of the 244 risk variants while accounting for the different sample sizes for the diseases, we used Bayesian multinomial regression. The aim is to estimate the posterior probability (Prob model ) for each disease model conditional on the genotype and phenotype data that were observed (Online Methods). A disease model is a set of diseases with which a given locus is associated (has a nonzero log-transformed odds ratio; for example, 'associated with Crohn's disease and ulcerative colitis but not with ankylosing spondylitis, psoriasis or PSC' is one disease model).
There are a total of 32 possible disease models for the five phenotypes, which include the null model ('not associated with any disease'). The Bayesian setting naturally handles the different uncertainties on the effect sizes for each disease resulting from their different sample sizes and powers.
We found 66 signals (59 non-MHC loci) with a best Prob model ≥60%, including 14 loci (with closest genes SH2B3, UBE2L3, TNP2, IL2RA, DNMT3B, CXCR2, CDKAL1, CARD9, MST1, ZMIZ1 and ETS1) with Prob model ≥0.8 ( Supplementary Table 3b ) when assuming that each sharing model is given the same probability (uniform prior across all models; Online Methods). However, because previous studies suggested that the structure of sharing in susceptibility is non-uniform 2 , we calculated posteriors for each model for each risk variant under six different priors and took a vote of the highest posterior models under each prior (Online Methods). We then counted how many priors voted for that model and calculated the minimum, maximum and mean (MeanProb model ) posterior for each Figure 1 Discovery of 27 new genome-wide significant disease associations (P disease < 5 × 10 −8 ) for ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis. Singledisease analyses were performed only on SNPs that achieved P SBM <5 × 10 −7 in the primary (unconditioned) cross-disease SBM approach. We identified 17 new genome-wide significant susceptibility loci for ankylosing spondylitis, 6 loci for Crohn's disease and 4 loci for PSC (supplementary table 2). Corresponding P values and odds ratios for each new association are shown separately for each disease. With this analysis, the numbers of known ankylosing spondylitis, IBD and PSC risk loci increase to 48, 206 and 20, respectively. For 22 of the 27 genome-wide significant associations, the lead SNPs from the SBM approach (P SBM < 5 × 10 −8 ) and the single-disease lookups (P SBM < 5 × 10 −7 and P disease < 5 × 10 −8 ) were identical; in 5 instances, we had different lead SNPs for the SBM and single-disease analyses (supplementary table 2). Negative log 10 -transformed P value (P disease ) from Immunochip analysis (supplementary table 2) is shown with respect to the physical locations of markers; the direction of each triangle denotes the direction of disease-individual effect. Odds ratios are from the five single diseases versus control subsearches (OR(disease) in supplementary table 2). Large circles denote nominally significant disease-individual P values (P disease < 0.05). CAF cases/controls represents the minor allele frequency in cases/controls. If relevant, the nearest gene within 10 kb of each variant is depicted. The red horizontal line indicates a genome-wide significance threshold of P = 5 × 10 −8 .
npg risk variant ( Supplementary Table 3c ). On the basis of this consensusfinding process of merging results from six different priors, we identified 34 signals (31 non-MHC loci) with a best MeanProb model ≥60%, including 12 loci (with closest genes SH2B3, IL2RA, IFIH1, NFKB1 and TYK2) with MeanProb model ≥0.8, suggesting that we correctly identified the disease model ( Table 1) . Of the 34 associations with MeanProb model ≥0.6, 25 signals had five diseases involved, 6 signals had four diseases involved and 3 signals were unique to a single disease. Some of these disease sets showed different directions of effect (risk versus protective), heterogeneity of odds ratios (P < 0.01), or both, for the diseases involved ( Table 1 and Supplementary Fig. 6 ).
Distinguishing pleiotropy from heterogeneity
Statistically significant temporal comorbidity (disease A followed by disease B within a 5-year time frame of disease A, or vice versa) among the five diseases studied was confirmed for eight of ten possible pairs of diseases (P < 0.05/823,606 = 1.21 × 10 −9 ) after screening 823,606 directed pairs of diagnoses from an electronic health registry covering the whole population of Denmark 5 (Online Methods and Supplementary Table 11 ). Consistent with previous reports, we further observed high comorbidity rates among our patients ( Supplementary Table 12 ): that is, patients had more than one disease at the time of last diagnosis. This may occur because of pleiotropy (sharing of risk alleles by disease A and disease B) or heterogeneity (a subgroup of disease A cases has a higher load of risk alleles for disease B). Heterogeneity can occur as the result of many different scenarios, including diagnostic misclassifications, molecular subtypes and excessive comorbidity. We evaluated whether pleiotropy or heterogeneity best explained the high comorbidity rates among the five diseases studied using BUHMBOX 20 (Online Methods). BUHMBOX detects heterogeneity by calculating the cross-locus correlation of disease B-associated loci among disease A cases; a nonzero correlation is indicative of heterogeneity 20 . We calculated the statistical power of BUHMBOX to detect various proportions of sample heterogeneity for all disease pairs (Online Methods). For 18 of the 20 pairs of diseases, we had >50% power to detect 20% sample heterogeneity ( Supplementary Fig. 10 and Supplementary  Table 13 ). Because BUHMBOX has high power for these pairs, Figure 6 for all ten pairwise comparisons. Even if disease associations account for approximately the same amount of variance explained in disease liability (for example, as seen here for psoriasis and ulcerative colitis), the pattern of sharing is complex in terms of the size and direction of effect. Each box represents an independently associated SNP for the given disease. The size of each box is proportional to the amount of heritability for that variant. The color of each box denotes whether the difference in variance explained is due to different direction of effect (risk versus protective), significant heterogeneity of odds ratios (P < 0.01) or both. npg A r t i c l e s non-significant BUHMBOX results would strongly suggest that the genetic risk score (GRS) association is likely due to pleiotropy rather than heterogeneity.
First, to quantify genetic sharing for each of the 20 possible pairs of five diseases, we used a GRS approach (Online Methods). We calculated GRSs for disease B (using known risk alleles, weighted by effect size) for all individuals in the disease A sample and tested the association of the GRSs with disease A status using logistic regression. The GRSs test for enrichment of disease B alleles in disease A cases and are expected to be significant in the presence of both pleiotropy and heterogeneity. As expected, we observed highly significant associations between disease B GRSs and disease A status for almost every possible pair ( Supplementary Table 14 ), which demonstrates strong sharing of risk alleles by the different immune-mediated diseases.
We then tested whether this observed genetic sharing was due to true pleiotropy or heterogeneity using BUHMBOX 20 . In the setting of pleiotropy, pleiotropic disease B risk alleles are shared across all disease A cases, whereas in heterogeneity only a subset of disease A cases share disease B risk alleles. This leads to cross-locus correlations between disease B-associated loci being positive in the presence of heterogeneity but not in the case of pleiotropy. BUHMBOX calculates the cross-locus correlation between disease B-associated loci in disease A cases and determines whether this correlation is significantly nonzero. We calculated cross-locus correlations for all 20 disease pairs (Online Methods). We did not observe significant interlocus correlations (Supplementary Table 14) , despite having high statistical power for many pairs (Supplementary Fig. 10 and Supplementary Table 13 ). Our findings suggest that the overall GRS association between the five immune diseases investigated is likely due to pleiotropy. Figure 3 Identification of drug-targeted genes in a core disease protein-protein interaction network. We evaluated the potential role of genes in drug discovery by linking genes from a core PPI network (supplementary Fig. 9 ) to drugs using DrugBank (Online Methods). All drugs were selected on the basis of evidence from phase I, II and/or III RCTs or published animal studies. Nine drug target genes overlap with the genes from the core network.
(a) Connections between biological genes from the core PPI network (red) and drugs (blue) used for treatment of ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis (yellow). (b) Connections between biological genes from the core PPI network (red) and drugs (blue) used for treatment of other inflammatory diseases and traits (yellow).
npg
Immunochip-wide coheritability analysis
To estimate Immunochip-wide pleiotropy (the genetic variation and covariation between pairs of diseases in liability that is tagged by SNPs represented on the Immunochip), we applied univariate and bivariate linear mixed-model heritability methods 21, 22 (Online Methods). The relationships between disorders are expressed as SNP-based coheritabilities ( Fig. 4) . When excluding SNPs from the MHC region, genetic correlation was highest between Crohn's disease and ulcerative colitis (r g = 0.78 ± 0.015 (standard error), in concordance with previous estimates 23 ) and PSC and ulcerative colitis (r g = 0.64 ± 0.027), moderate (r g <0.5) between ankylosing spondylitis and Crohn's disease (r g = 0.49 ± 0.023), ankylosing spondylitis and ulcerative colitis (r g = 0.47 ± 0.026), Crohn's disease and PSC (r g = 0.35 ± 0.030), ankylosing spondylitis and PSC (r g = 0.33 ± 0.035), ankylosing spondylitis and psoriasis (r g = 0.28 ± 0.035) and Crohn's disease and psoriasis (r g = 0.27 ± 0.029), and low (r g <0. 25 ) between psoriasis and PSC (r g = 0.18 ± 0.042) and psoriasis and ulcerative colitis (r g = 0.16 ± 0.034) ( Supplementary Figs. 11 and 12, and Supplementary Table 15 ).
For correlation values including MHC variants, see Supplementary  Table 15 . As a negative control, we conducted coheritability analyses between each immune-mediated disease under study and longevity, bipolar disorder, major depressive disorder and schizophrenia Immunochip studies (Supplementary Fig. 13) . No coheritability was observed with the non-immune-mediated diseases studied here.
DISCUSSION
By combined assessments of Immunochip genotyping data sets from 52,262 patients with five closely associated conditions (ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis; all seronegative inflammatory diseases according to clinical definition) and 34,213 healthy controls, we were able to delineate the genetic overlap between the conditions. A key outcome of the overlap analysis is that, despite the profound pleiotropy, clear demarcations of the genetic risk for the individual conditions exist. Implicit to this, and npg A r t i c l e s hence in conflict with an existing paradigm where a causal relationship exists between IBD and involved extraintestinal conditions 24, 25 , our modeling rather supports (i) the presence of shared pathophysiological pathways as the basis for clinical co-occurrence and (ii) the hypothesis that patients with concomitant syndromes are genetically distinct from patients without concomitant syndromes. Our cross-disease association framework also enabled the identification of new coding variants and known eQTLs. One newly identified missense variant for Crohn's disease, rs4986790, is located in exon 3 of TLR4 (encoding Toll-like receptor 4), which is an important mediator of innate immunity. This SNP has been shown to modulate TLR4 effector functions either by interfering with the binding capacity of TLR4 for its ligands or by controlling the extracellular deposition of functional TLR4 (refs. 26, 27) . Another newly identified missense SNP for Crohn's disease, rs2236379, which has not been previously associated with other disease traits, is located in exon 9 of PRKCQ encoding protein kinase C-θ (PKC-θ). PKC-θ is essential in the signaling cascades that lead to NF-κB, AP-1 and NFAT activation 28 and is also critical for stabilizing the helper type 17 (T H 17) T cell phenotype by selective suppression of the STAT4-interferon-α (IFN-c)-T-bet axis at the onset of differentiation 29 . Furthermore, PKC-θ inhibition enhances regulatory T cell (T reg ) function and protects T reg cells from inactivation by tumor necrosis factor (TNF)-α, restores the activity of defective T reg cells from patients with rheumatoid arthritis and enhances the protection of mice from inflammatory colitis 30 . We also found that one of the secondary signals for ankylosing spondylitis and ulcerative colitis, rs61802846, is in perfect LD (r 2 = 1.0) with a stop-gain SNP, rs9427397, resulting in a premature stop codon in FCGR2A. This signal appears to be distinct (r 2 = 0.12) from the known IBD-associated missense variant in FCGR2A (rs1801274) 1, 31 . Among the ten strongest eQTL SNPs (P FDR < 0.05; Supplementary Fig. 4 and Supplementary Table 6 ) are the intronic SNP rs3766606 in PARK7 (shared by psoriasis (risk) and Crohn's disease and ulcerative colitis (protective)), the intronic variant rs2910686 in ERAP2 (shared by ankylosing spondylitis, Crohn's disease and ulcerative colitis (risk only)), the intronic SNP rs1893592 in UBASH3A (shared by PSC and ulcerative colitis (protective)), the missense SNP rs12720356 in TYK2 (shared by ankylosing spondylitis, Crohn's disease and ulcerative colitis (risk) and psoriasis (protective)) and the intronic variant rs679574 in FUT2 (shared by ankylosing spondylitis, Crohn's disease, psoriasis and PSC (risk only)).
Most 'shared' loci exhibit complex patterns of multidisease association, suggesting multiple types of pleiotropy 32 . Through subsequent Bayesian multinomial regression modeling, we identified 31 loci with 34 independent associations ( Table 1) for which we determined a specific disease model constellation with high certainty (MeanProb model ≥60%). For example, at 12q24.12 (locus 119; SH2B3), the single lead SNP rs3184504 (Prob = 0.98) is associated with decreased risk of ankylosing spondylitis (odds ratio (OR AS ) = 0.92) but with increased risk of the other diseases (OR CD = 1.06, OR PS = 1.06, OR PSC = 1.19 and OR UC = 1.05) and has been associated before with >10 other phenotypes in the GWAS catalog 10 , thus suggesting that 12q24.12 is a common risk locus with heterogeneous effect sizes for multiple complex diseases.
In addition to contrasting the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis, we investigated comorbidity and pleiotropy among these phenotypes. GRS and cross-locus correlation analyses 20 suggest that the increased comorbidity rates among our patients are due to biological pleiotropy rather than heterogeneity. In other words, an individual with a pleiotropic risk variant is more likely to acquire both diseases. Among all the disease pairs with a nonzero comorbidity rate, the pair of PSC and IBD is particularly noteworthy for its high frequency of comorbidity ( Supplementary Table 12 ). Patients with PSC suffer from a highly increased frequency (62-83%) of IBD 33 (called PSC with concomitant IBD, or PSC-IBD, although IBD is most often classified as ulcerative colitis). Interestingly, despite the high prevalence of IBD in PSC, the loci encoding IL23R and IL10 (both of which are strongly associated with Crohn's disease and ulcerative colitis) did not show any evidence of association with PSC. However, we found that many PSC risk variants are shared with ulcerative colitis and have similar effects in terms of both magnitude and direction (Supplementary Fig. 6 ). It is unlikely that pleiotropy with ulcerative colitis by itself accounts for the comorbidity with IBD seen in PSC, given the exceedingly higher prevalence of IBD in patients with PSC as compared to the population prevalence of ulcerative colitis. We therefore questioned whether PSC-IBD is a unique disease distinct from ulcerative colitis or whether PSC-IBD is the result of ulcerative colitis that is prevalent among patients with PSC because of a causal relationship between the two diseases (that is, ulcerative colitis causes subsequent development of PSC, or vice versa). If the PSC-IBD phenotype is the result of a causal relationship between ulcerative colitis and PSC, there would be a subgroup of PSC cases with a higher load of ulcerative colitis risk alleles (or vice versa). We tested ulcerative colitis loci in PSC cases with BUHMBOX and found no evidence of an ulcerative colitis-driven subgroup (Supplementary Table 14) , despite high power (99.9% power given the hypothesis that 62% of PSC cases are affected by ulcerative colitis). We also tested PSC loci in ulcerative colitis cases with BUHMBOX (Supplementary Table 14) ; although the result was negative (P = 0.48), the test was underpowered to detect subtle heterogeneity proportions. Although we cannot completely rule out a causal relationship between PSC and ulcerative colitis at this time, we expect that these findings will become clearer as additional PSC-associated loci are identified in future studies, improving power to detect heterogeneity. At present, our findings are most consistent npg with the hypothesis that PSC-IBD is a unique disease that shares some genetic factors with ulcerative colitis but is distinct from classical IBD phenotypes 4, 34 . This hypothesis is further supported by the observation that PSC-IBD shows clinical differences from classical IBD and requires specialized management; in comparison to IBD, PSC-IBD has a higher rate of pancolitis with ileitis and rectal sparing, as well as a higher incidence of colorectal cancer 34 .
Our results from testing of enrichment between multidisease signals and large-scale expression data sets together with epigenetic and expressed enhancer profiles further reflect this extensive pleiotropy and mainly highlight perturbations in immune response pathways and blood cell tissues. However, we could not pinpoint which genomic features and which cells a variant influences. We propose that larger gene expression data sets for the disease-relevant tissues and cell types from affected individuals should be generated to allow for high resolution and more eQTL studies, as eQTLs are often cell type specific 35 . Further, the discovery of multiple additional genetic associations increases the power of such analyses to define pathways and cell types involved in specific diseases.
In summary, we performed the largest systematic cross-disease genetic study for chronic immune-mediated diseases thus far. Using novel cross-phenotype analytical methodologies, we identified 17 new genome-wide significant susceptibility loci for ankylosing spondylitis, 6 loci for Crohn's disease and 4 loci for PSC, and we identified 3 new, as yet unreported risk loci for the diseases under study. With this, the numbers of known ankylosing spondylitis, IBD and PSC risk loci are increased to 48, 206 and 20, respectively. Because of lower coverage at unselected regions on the Immunochip, imputed GWAS data would further increase statistical power to identify new shared associations outside established risk loci in future studies. Future cross-disease studies of a wider range of phenotypes, in combination with more sophisticated fine-mapping studies on individual diseases and specific layers of multi-omics data sets, are needed to provide another layer of information for a potential new disease classification based on molecular genetic profiles. Whereas most cross-disease studies employ patient panels that were manually curated for single phenotypes and often rely on questionnaire data, future studies could employ even larger collections of hospitalized patients, for whom exhaustive electronic medical patient records and array data exist. Moreover, longitudinal data from electronic health charts could pinpoint further comorbidities that should be included in a more systematic next-generation cross-disease approach. 
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METhODS
Methods and any associated references are available in the online version of the paper. Accession codes. Data access was granted by the management committees of the main disease consortia (the International IBD Genetics Consortium (IIBDGC), the International Genetics of Ankylosing Spondylitis Consortium (IGAS), the International PSC Study Group (IPSCSG), the Genetic Analysis of Psoriasis Consortium (GAPC) and the Psoriasis Association Genetics Extension (PAGE)). The genotype data are not freely accessible, but access can be obtained by submitting an application to the respective management committees, institutions or data owners.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. stepwise regression to condition away lead SNPs one at a time until no associations remained, following a recently published stepwise conditional SBM fine-mapping approach 9 . This is an effective method for separating independent signals and assumes that LD between the independent causal variants is low. Significance was defined by Bonferroni correction of the number of LD-independent markers on the Immunochip (0.05/37,377 = 1.34 × 10 −6 ).
Cluster plot inspection.
Immunochip intensity cluster plots of all genome-wide significant SNP markers (P SBM < 5 × 10 −7 and P disease < 5 × 10 −8 ; P SBM < 5 × 10 −8 ) from Supplementary Tables 2 and 3 were manually inspected by three different persons using Evoker 50 to ensure that they were well clustered.
Bayesian multinomial regression for model selection. To compare different disease models at each locus, we used Bayesian multinomial regression. A disease model is a list of the diseases with which a given locus is associated (has a nonzero log-transformed odds ratio; for example, 'associated with Crohn's disease and ulcerative colitis but not with psoriasis, ankylosing spondylitis or PSC' is one disease model, as is 'associated with all diseases'). There are a total of 32 possible disease models for the five phenotypes, which includes the null model ('not associated with any disease'). Our aim is to infer the posterior probability for each of these disease models, conditional on the genotype and phenotype data we have. We do this under a Bayesian setting, as it naturally handles the different uncertainties on the effect sizes for each disease due to their different sample sizes and powers. The methods we describe below are implemented in the open source Trinculo software package.
The Bayesian multinomial logistic regression software calculates a marginal likelihood for each model, integrating out uncertainty in the effect size as
where β is a vector of log-transformed odds ratios for each disease D.
The likelihood Pr(D|M) is given by the multinomial logistic likelihood. The prior distribution on the effect sizes is given by β|M ~MVN(0,Σ M ), where Σ M is the prior covariance matrix for model M. To enforce phenotypes that are not associated with the disease, we set = ∑ 0 ij M if either phenotype i or j is not associated with the locus. We use Newton's method to calculate the maximum a posteriori estimate (MAP) for the parameters and calculate the marginal likelihood using a Laplace approximation around the MAP. We calculate the posterior probability for each model as For the per-model priors, we use (i) a uniform prior across all models, (ii) a uniform prior across the number of phenotypes associated with the locus (all models where there are the same number of associations summing to 1/6) with equal weight to each model with the same number of phenotypes, and (iii) an empirical prior distribution on the number of phenotypes associated with the locus, inferred by maximum likelihood. We calculated posteriors for each model for each risk variant under the six different priors. For each risk variant, we then took a vote of the highest posterior models under each prior, such that we select whichever model was considered best by the largest number of priors. We also recorded how many priors voted for that model and how much posterior each prior gave to the winning model.
If SNPs represented secondary independent association signals identified from stepwise conditional SBM analysis, then they were tested conditional on all other identified genome-wide significant independent signals within the same locus. Within the Bayesian logistic regression, we included the genotype at the lead SNP (and further preceding independent signals) as a covariate in the model.
Disease correlation measure and temporal comorbidity.
To determine significant temporal co-occurrences (disease pairs) for the five inflammatory diseases under study, we screened an independent data set covering ICD10 diagnosis codes from 6,631,920 people of the entire Danish population in the period from 1996 to 2014 (ref. 5). We used relative risk to measure the strength of the correlation between a pair of diagnoses (diagnosis A followed by diagnosis B). Relative risk estimates and associated P values were calculated using a sampling approach as described in the original study 5 . In brief, given a pair, diagnosis A followed by diagnosis B, relative risk of a temporal association was calculated as the ratio of the observed number of patients who had disease A then disease B within 5 years and the number of randomly matched control patients diagnosed with disease B within 5 years of a matched discharge. Each matched control was of the same age (birth decade) and sex as the case and had a discharge of the same type (inpatient, outpatient or emergency room) within the same calendar week as the case diagnosed with disease A (from which the 5 years to develop disease B was calculated). The significance threshold of P = 0.05/823,606 = 1.21 × 10 −9 was applied using Bonferroni correction for the testing of 823,606 directed pairs in the original study 5 .
Distinguishing pleiotropy and heterogeneity. We used BUHMBOX v0.38 (Breaking Up Heterogeneous Mixture Based On Cross-Locus Correlations) 20 to evaluate whether the sharing of risk alleles observed across pairs of diseases (disease A and disease B) was driven by true pleiotropy (where there is pervasive sharing of risk alleles by two diseases) or by heterogeneity (where a subgroup of disease A cases has a higher burden of risk alleles for disease B). The BUHMBOX approach has been described in detail elsewhere 20 . Briefly, a GRS approach is used to detect significant sharing of risk loci by disease A and disease B. If such genetic sharing is detected using GRSs, the BUHMBOX test statistic (which identifies heterogeneity by calculating the cross-locus correlation of disease B-associated loci among disease A cases) is applied to verify whether these associations are due to heterogeneity (for example, sample misdiagnosis or excessive comorbidity) as opposed to biological pleiotropy. In the setting of pleiotropy, pleiotropic disease B risk alleles are shared across all disease A cases, whereas in heterogeneity only a subset of disease A cases share disease B risk alleles. Thus, cross-locus correlations between disease B-associated loci are positive in the presence of heterogeneity but not in the case of pleiotropy. To strictly control for false positives, BUHMBOX uses LD pruning, the top seven principal components from PCA and delta-correlations between cases and controls.
First, to quantify pleiotropy for each of the 20 possible pairs of five diseases, we calculated GRSs using known independent risk loci for disease B for each case and control in the disease A sample (based on disease B risk alleles, weighted by effect size) and tested the association of these GRSs with disease A status using logistic regression adjusted for the top seven principal components from PCA. The GRS P values therefore test for enrichment of disease B risk alleles in disease A and are expected to be significant in the presence of both pleiotropy and heterogeneity. We obtained the list of known associated loci from the previous literature 1, [36] [37] [38] for ankylosing spondylitis, Crohn's disease, psoriasis, PSC and ulcerative colitis.
Next, we evaluated the presence of heterogeneity by applying BUHMBOX 20 to each of the 20 pairs of diseases. We estimated the statistical power of BUHMBOX to detect a certain proportion of sample heterogeneity by simulation ( Supplementary Fig. 10 and Supplementary Table 13 ), using the effect sizes and allele frequencies of the disease B loci and randomly simulating the number of cases and controls in the disease A sample.
Functional annotation of associated variants.
The variants identified in this study were annotated using the Ensembl variant effect predictor (VEP) 51 npg (release 77) to determine genomic position annotations, including the closest gene, and functional consequences (using the most severe consequence from SIFT 52 and PolyPhen 53 ). The --assembly flag was set to GRCh37 and the --pick flag was added to retrieve the most severe consequence for the variants. The UpDownDistance plugin was used to retrieve the nearest gene ID within 10 kb of the variant. TSS distance was retrieved using the TSSDistance plugin. We also included the --regulatory flag to annotate where a variant overlaps a regulatory feature. The DNase hypersensitivity site (DHS) and promoter annotations were taken from 1000 Genomes Project annotations 54 .
To determine whether any of the lead variants were in high LD (r 2 >0.8) with a functional variant, the 1000 Genomes Project v3 EUR haplotypes were used (1000 Genomes Phase III 20130502 release). Pairwise LD was calculated between the lead SNPs and all other SNPs in this data set using PLINK (v1.09) 55 . Only variants that occurred in the 1000 Genomes Project data set were included in this analysis. The GWAS catalog 10 was used to determine whether any lead variants or variants in high LD (r 2 >0.8) with the lead variants had previously been reported in other GWAS. ImmunoBase and Europe PubMed Central were also used to determine whether variants had previously been associated with an autoimmune phenotype.
